Goldman Sachs Group has declared to the AMF that, on February 13, it exceeded the thresholds of 5% of the capital and voting rights of GenSight Biologics and held, through Goldman Sachs International, 6.80% of the capital and voting rights of this company.

This crossing of thresholds results from an off-market acquisition of GenSight Biologics shares and an increase in the number of shares held by assimilation. Goldman Sachs International crossed the same thresholds individually.

Copyright (c) 2024 CercleFinance.com. All rights reserved.